Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model

This publication has 22 references indexed in Scilit:

• Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions
  Life Sciences, 2010
• Change in P-glycoprotein and caveolin protein expression in brain striatum capillaries in New Zealand Obese mice with type 2 diabetes
  Life Sciences, 2009
• Metabolic Syndrome and All-Cause and Cardiovascular Disease Mortality Japan Public Health Center-Based Prospective (JPHC) Study
  Circulation Journal, 2009
• Peroxisome Proliferator‐Activated Receptor δ‐Agonist, GW501516, Ameliorates Insulin Resistance, Improves Dyslipidaemia in Monosodium l‐Glutamate Metabolic Syndrome Mice
  Basic & Clinical Pharmacology & Toxicology, 2008
• Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P‐glycoprotein up‐regulation at the blood‐brain barrier
  The FASEB Journal, 2008
• Concise Review: Clinical Relevance of Drug–Drug and Herb–Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein)
  The Oncologist, 2007
• Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels
  Inflammatory Bowel Diseases, 2007
• Preclinical study of a “tailor-made” combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa™) for disseminated peritoneal scirrhous gastric cancer
  International Journal of Cancer, 2005
• Permeability Dominates in Vivo Intestinal Absorption of P-gp Substrate with High Solubility and High Permeability
  Molecular Pharmaceutics, 2005
• Brain Lesions, Obesity, and Other Disturbances in Mice Treated with Monosodium Glutamate
  Science, 1969